The Use of Monoamine Pharmacological Agents in the Treatment of Sexual Dysfunction: Evidence in the Literature

Journal of Sexual Medicine

Volumn 8, Issue 4, 2011, Pages 956-970

  Moll, Jennifer L ^a   Brown, Candace S ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Antidepressants; Dopamine; Monoamines; Serotonin; Sexual Dysfunction

Indexed keywords

AGOMELATINE; AMANTADINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; APOMORPHINE; BROMOCRIPTINE; BUSPIRONE; CYPROHEPTADINE; DEXAMPHETAMINE; DOPAMINE RECEPTOR; FLIBANSERIN; FLUOXETINE; GENERIC DRUG; GEPIRONE; GRANISETRON; METHYLPHENIDATE; MIRTAZAPINE; MONOAMINE; NEFAZODONE; PAROXETINE; PEMOLINE; PERGOLIDE; PRAMIPEXOLE; PSYCHOSTIMULANT AGENT; ROPINIROLE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; UNINDEXED DRUG;

ADJUVANT THERAPY; ANOREXIA; ANORGASMIA; ANXIETY DISORDER; BINDING AFFINITY; BRIEF INDEX OF SEXUAL FUNCTIONING; CHANGES IN SEXUAL FUNCTIONING QUESTIONNAIRE; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DIZZINESS; DOPAMINERGIC SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EVENING DOSAGE; FEMALE; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; HYPERSEXUALITY; HYPOTENSION; INTERNATIONAL INDEX OF ERECTILE FUNCTIONING QUESTIONNAIRE; LIBIDO DISORDER; LIVER TOXICITY; MAJOR DEPRESSION; MALE; MONOAMINERGIC SYSTEM; NAUSEA; NONHUMAN; PARKINSON DISEASE; PATIENT COMPLIANCE; PENIS ERECTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RESTLESS LEGS SYNDROME; REVIEW; SCORING SYSTEM; SEROTONIN SYNDROME; SEROTONINERGIC SYSTEM; SEXUAL AROUSAL; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URTICARIA; WEIGHT GAIN;

EID: 79953301326     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.02190.x     Document Type: Article

References (95)

1. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA 1999;281:537-44.
2. Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA 1999;281:537-44.
3. Hirschfield RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatr 2000;61(6 suppl):4-6.
4. Zajecka J. Strategies for treatment of antidepressant-related sexual dysfunction. J Clin Psychiatr 2001;62:35-43.
5. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. J Clin Psychiatr 2001;62(3 suppl):10-21.
6. Pfaus JG. Pathways of sexual desire. J Sex Med 2009;6:1506-33.
7. Factor SA. Dopamine agonists. Med Clin North Am 1999;83:415-43.
8. Giuliano F, Allard J. Dopamine and sexual dysfunction. Int J Impot Res 2001;13:S18-28.
9. Brown AD, Blagg J, Reynolds DS. Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today 2007;12:757-65.
10. Baldessarini RJ, Kula NS, McGrath CR, Bakthavachalam V, Kebabian JW, Neumeyer JL. Isomeric selectivity at dopamine D3 receptors. Eur J Pharmacol 1993;239:269-70.
11. Muir JW, Besser GM, Edwards CRW, Rees LH, Cattell WR, Ackrill P, Baker LR. Bromocriptine improves reduced libido and potency in men receiving maintenance hemodialysis. Clin Nephrol 1983;20:308-14.
12. Bommer J, del Pozo E, Ritz E, Bommer G. Improved sexual function in male hemodialysis patients on bromocriptine. Lancet 1979;8:496-7.
13. Ambrosi B, Bara R, Faglia G. Bromocriptine in impotence. Lancet 1977;5:987.
14. Pohanka M, Kanovsky P, Bares M, Pulkrábek J, Rektor I. The long lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: Evidence from the results of an open, prospective one year trial. Parkinsonism Rel Dis 2005;11:509-12.
15. Balogh S, Hendricks SE, Kang J. Treatment of fluoxetine induced anorgasmia with amantadine. J Clin Psychiatry 1992;53:212-3.
16. Shrivastava RK, Shrivastava S, Overweg N, Schmitt M. Amantadine in the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1995;15:83-4.
17. Balon R. Intermittent amantadine for fluoxetine-induced anorgasmia. J Sex Marit Ther 1996;22:290-2.
18. O'Sullivan JD, Hughes AJ. Apomorphine-induced penile erections in Parkinson's disease. Mov Disord 1998;13:536-9.
19. Pavone C, Anello G, Serretta V, Serretta V, Almasio PL, Pavone-Macaluso M. Prospective, randomized cross-over comparison of sublingual apomorphine with oral sildenafil for male erectile dysfunction. J Urol 2004;172:2347-9.
20. Caruso S, Agnello C, Intelisano G, Farina M, DiMari L, Ciani A. Placebo controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder. Urology 2004;63:955-9.
21. Bechara A, Bertolino MV, Casabe A, Fredotovich N. A double-blinded randomized placebo control study comparing the objective and subjective changes in female sexual response using sublingual apomorphine. J Sex Med 2004;1:209-14.
22. Worthington JJ, Simon NM, Korbly NB, Perlis RH, Pollack MH. Anxiety Disorders Research Program. Ropinirole for antidepressant-induced sexual dysfunction. Int Clin Psychopharmacol 2000;17:307-10.
23. Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog E. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Rel Disord 2005;11:381-6.
24. Aiken CB. Pramipexole in psychiatry: A systematic review of the literature. J Clin Psychiatr 2007;68:1230-6.
25. Munhoz RP, Fabiani G, Becker N, Teive HA. Increased frequency and range of sexual behavior in a patient with Parkinson's disease after use of pramipexole: A case report. J Sex Med 2009;6:1177-80.
26. Pae CU, Marks DM, Masand P, Peindl K, Hooper-Wood C, Han C, Mannelli P, Ciccone P, Patkar AA. Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: Results from a 4-week, double-blinded, placebo-controlled trial. Clin Neuropharmacol 2009;32:85-8.
27. Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO. Methylphenidate augmentation of serotonin selective reuptake inhibitors: A case series. J Clin Psychiatry 1996;57:72-6.
28. Roeloffs C, Bartlik B, Kaplan PM, Kocsis JH. Methylphenidate and SSRI-induced sexual side effects. J Clin Psychiatry 1996;57:548.
29. Gitlin MJ. Treatment of sexual side effects with dopaminergic agents. Reversal of sexual dysfunction induced by SSRIs and phenelzine with pemoline and dextroamphetamine. J Clin Psychiatry 1995;56:3.
30. Balon R, Segraves RT. Survey of treatment practices for sexual dysfunction associated with antidepressants. J Sex Marital Ther 2008;34:353-65.
31. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E. Bupropion: A review of its mechanism of antidepressant activity. J Clin Psychiatr 1995;56:395-401.
32. Stahl SM, Prado JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004;6:159-66.
33. Kavoussi RJ, Segraves RT, Hughes AR, Ascher JA, Johnston JA. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatr 1997;58:532-7.
34. Croft H, Settle EC, Houser TL, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant and sexual functioning effects of bupropion SR and sertraline. Clin Ther 1999;21:643-58.
35. Coleman CC, Cunningham LA, Foster VJ, Batey SR, Donahue RMJ, Houser TL, Ascher JA. Sexual dysfunction associated with the treatment of depression: A placebo-controlled comparison of bupropion and sertraline treatment. Ann Clin Psychiatry 1999;11:205-15.
36. Coleman CC, King B, Bolden-Watson C, Book MJ, Segraves RT, Richard N, Ascher J, Batey S, Jamerson B, Metz A. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001;23:1040-58.
37. Clayton AH, Croft HA, Horrigan JP, Wightman DS, Krishen A, Richard NE, Modell JG. Bupropion extended release compared with escitalopram: Effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006;67:736-46.
38. Segraves RT, Kovoussi R, Hughes AR, Batey SR, Johnston JA, Donahue R, Ascher JA. Evaluation of sexual functioning in depressed outpatients: A double-blind comparison of bupropion sustained release and sertraline treatment. J Clin Psychopharmacol 2000;20:122-8.
39. Clayton AH, Warnock J, Korenstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 2004;65:62-7.
40. Dobkin RD, Menza M, Marin H, Allen LA, Rousso R, Leiblum SR. Bupropion improves sexual functioning in depressed minority women: An open-label switch study. J Clin Psychopharmacol 2006;26:21-6.
41. Clayton AH, McGarvey EL, Abouesh AI, Pinkerton RC. Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. J Clin Psychiatry 2001;62:185-90.
42. Walker PW, Cole JO, Gardner EA, Hughes AR, Johnston JA, Batey SR, Lineberry CG. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatr 1993;54:459-65.
43. Ashton AK, Rosen RC. Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 1998;59:112-5.
44. Gitlin MJ, Suri R, Altshuler L, Zuckerbrow-Miller J, Fairbanks L. Bupropion sustained release as a treatment of SSRI-induced sexual side effects. J Sex Marital Ther 2002;28:131-8.
45. Kennedy SH, McCann SM, Masellis M, McIntyre RS, Raskin J, McKay G, Baker GB. Combining bupropion SR with venlafaxine, paroxetine, and fluoxetine: A preliminary report on pharmacokinetic, therapeutic and sexual dysfunction effects. J Clin Psychiatry 2002;63:181-6.
46. Labbate LA, Pollack MH. Treatment of fluoxetine-induced sexual dysfunction with bupropion: A case report. Ann Clin Psychiatr 1994;6:13-5.
47. DeBattista C, Solvason B, Poirier J, Kendrick E, Loraas E. A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. J Clin Psychiatry 2005;66:844-8.
48. Masand PS, Ashton AK, Gupta S, et Frank B. Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: A randomized, double-blind, placebo-controlled, parallel-group study. Am J Psychiatr 2001;158:850-7.
49. Crenshaw TL, Goldberg JP, Stern WC. Pharmacologic modification of psychosexual dysfunction. J Sex Marital Ther 1987;13:239-52.
50. Modell JG, May RS, Katholi CR. Effect of bupropion-SR on orgasmic dysfunction in nondepressed subjects: A pilot study. J Sex Marital Ther 2000;26:231-40.
51. Segraves RT, Croft H, Kavoussi R, Ascher JA, Batey SR, Foster VJ, Bolden-Watson C, Metz A. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J Sex Marital Ther 2001;27:303-16.
52. Segraves RT, Clayton A, Croft MD, Wolf A, Warnock J. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J Clin Psychopharmacol 2004;24:339-42.
53. Terry AV, Buccafusco JJ, Wilson C. Cognitive dysfunction in neuropsychiatric disorders: Selected serotonin receptor subtypes as therapeutic targets. Behav Brain Res 2008;195:30-8.
54. Frohlich PF, Meston CM. Evidence that serotonin affects female sexual functioning via peripheral mechanisms. Physiol Behav 2000;71:383-93.
55. McCormick S, Olin J, Brotman AW. Reversal of fluoxetine-induced anorgasmia by cyproheptadine in two patients. J Clin Psychiatr 1990;51:383-4.
56. Aizenberg D, Zemishlany Z, Weizman A. Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol 1995;18:320-4.
57. Ashton AK, Hamer R, Rosen RC. Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment: A large-scale retrospective study of 596 psychiatric patients. J Sex Marit Ther 1997;23:165-75.
58. Cohen AJ. Fluoxetine induced yawning and anorgasmia reversed by cyproheptadine treatment. Am J Psychiatr 1992;53:5.
59. Feder R. Reversal of antidepressant activity by fluoxetine by cyproheptadine in three patients. J Clin Psychiatr 1991;52:163-4.
60. Lauerma H. Successful treatment of citalopram-induced anorgasmia by cyproheptadine. Acta Psychiatr Scand 1996;93:69-70.
61. Decastro RM. Reversal of MAOI-induced anorgasmia with cyproheptadine. Am J Psychiatr 1985;142:783.
62. Riley AJ, Riley EJ. Cyproheptadine and antidepressant-induced anorgasmia. Br J Psychiatr 1986;148:217-8.
63. Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS. Nefazodone versus sertraline in outpatients with major depression: Focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatr 1996;57(2 suppl):53-62.
64. Ferguson JM, Shrivastava RK, Stahl SM, Hartford JT, Borian F, Ieni J, McQuade RD, Jody D. Reemergence of sexual dysfunction in patients with major depressive disorder: Double-blind comparison of nefazodone and sertraline. J Clin Psychiatr 2001;62:24-9.
65. Zajecka J, Dunner DL, Gelenberg AJ, Hirshfield RMA, Kornstein SG, Ninan PT, Rush AJ, Thase ME, Trivedi MH, Arnow BA, Borian FE, Manber R, Keller MB. Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. J Clin Psychiatr 2002;63:709-16.
66. Boyarsky BK, Haque W, Rouleau MR, Hirschfeld RM. Sexual functioning in depressed outpatients taking mirtazapine. Depress Anxiety 1999;9:175-9.
67. Koutoutvidis N, Pratikakis M, Fotiadou A. The use of mirtazapine in a group of 11 patients following poor compliance to selective serotonin reuptake inhibitor treatment due to sexual dysfunction. Int Clin Psychopharmacol 1999;14:253-5.
68. Gelenberg AJ, Laukes C, McGahuey C, Okayli G, Moreno F, Zentner L, Delgado P. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry 2000;61:356-60.
69. Ozmenler NK, Karlidere T, Bozkurt A, Yetkin S, Doruk A, Sutcigil L, Canserver A, Uzun O, Ozgen F, Ozsahin A. Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors. Human Psychopharmacol 2008;23:321-6.
70. Michelson D, Kociban K, Tamura R Morrison MF. Mirtazapine, yohimbine, or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: A randomized, placebo controlled trial. J Psychiat Res 2002;36:147-52.
71. Farah A. Lack of sexual adverse effects with mirtazapine. Am J Health Sys Pharm 1998;55:2195-6.
72. Farah A. Relief of SSRI-induced sexual dysfunction with mirtazapine treatment. J Clin Psychiatr 1999;60:260-1.
73. Nelson EB, Keck PE Jr, McElroy SL. Resolution of fluoxetine-induced sexual dysfunction with the 5-HT3 antagonist granisetron [letter]. J Clin Psychiatry 1997;58:496-7.
74. Nelson EB, Shah VN, Welge JA, Keck PE Jr. A placebo-controlled, crossover trial of granisetron in SRI-induced sexual dysfunction. J Clin Psychiatry 2001;62:469-73.
75. Jespersen S, Berk M, Van Wyk C, Dean O, Dodd S, Szabo CP, Maud C. A pilot randomized, double-blind, placebo-controlled study of granisetron in the treatment of sexual dysfunction in women associated with antidepressant use. Int Clin Psychopharmacol 2004;19:161-4.
76. Landen MSG, Eriksson E, Agren H, Fahlen T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1999;19:268-71.
77. Othmer E, Othmer SC. Effect of buspirone on sexual dysfunction in patients with generalized anxiety disorder. J Clin Psychiatry 1987;48:201-3.
78. Norden MJ. Buspirone treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. Depression 1994;2:109-12.
79. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13.
80. Paluchowska MH, Bugno R, Bojarski AJ, Charakchieva-Minol S, Duszyńska B, Tatarczyńska E, Kłodzińska A, Stachowicz K, Chojnacka-Wójcik E. Novel, flexible, and conformationally defined analogs of gepirone: Synthesis and 5-HT1A, 5-HT2A, and D2 receptor activity. Bioorg Med Chem 2005;13:1195-200.
81. Yocca FD. Neurochemistry and neurophysiology of buspirone and gepirone: Interactions at presynaptic and postsynaptic 5-HT1A receptors. J Clin Psychopharmacol 1990;10(3 suppl):6S-12S.
82. Feiger AD, Heister JF, Shrivastava RK, Weiss KJ, Smith WT, Sitsen JMA, Gilbertini M. Gepirone extended release: New evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatr 2003;64:243-9.
83. Alpert JE, Franznick DA, Hollander SB, Fava M. Gepirone extended-release treatment of anxious depression: Evidence from a retrospective subgroup analysis in patients with major depressive disorder. J Clin Psychiatr 2004;65:1069-75.
84. DeRogatis LR, Brown CS. Gepirone ER treatment of symptoms of sexual dysfunction in women with major depressive disorder (MDD). Abstract 2009.
85. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S. Pharmacology of flibanserin. CNS Drug Rev 2002;8:117-42.
86. Kennedy S. Flibanserin: Initial evidence of efficacy on sexual dysfunction in patients with major depressive disorder. J Sex Med 2010;7:3449-59.
87. Clayton AH, Jolly E, Thorp J, Lewis-D'Agostino DJ, Wunderlich G, Lesko L. Baseline characteristics of patients enrolled in three Phase III North American trials of flibanserin in premenopausal women with hypoactive sexual desire disorder. J Sex Med 2009;6(2 suppl):45.
88. Goldfischer ER, Breaux J, Katz M, Kaufman J, Smith WB, Patel P, Mikl J, Sand M, Pyke R. Efficacy of continued flibanserin treatment in premenopausal women with hypoactive sexual desire disorder: Results from the ROSE Study. J Sex Med 2009;6(2 suppl):45.
89. th Congress. Lyon, France; 2009.
90. WebMD-2010-06-21. Medscape Medical News: FDA Advisory Committee votes against flibanserin for hypoactive sexual disorder. June 21, 2010.
91. Boehringer Ingelheim. Following regulatory feedback Boehringer Ingelheim decides to discontinue flibanserin development. Press Release issued October 8, 2010.
92. Goodwin GM, Emsley R, Rembry S, Rouillon F. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: A 24 week randomized, double-blind placebo controlled trial. J Clin Psychiatry 2009;70:1128-37.
93. deBodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ. Agomelatine, the first melatonergic antidepressant: Discovery, characterization, and development. Nat Rev Drug Disc 2010;9:628-42.
94. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008;28:329-33.
95. Montejo AL, Prieto N, Terleira A, Matias J, Alonso S, Paniagua G, Naval S, Parra DG, Gabriel C, Mocaer E, Portoles A. Better sexual acceptability of agomelatine compared to paroxetine in healthy male volunteers using the PRSexDQ Scale. Eur J Neuropsychopharmacol 2007;17:S349.